Wells Fargo lowered the firm’s price target on Arcturus Therapeutics (ARCT) to $45 from $50 and keeps an Overweight rating on the shares. The firm highlights potential upside on Phase 2 readout from the company’s CF program in mid-2025, where its expects positive efficacy and differentiated safety.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARCT:
- Arcturus Therapeutics: Strategic Focus and Promising CF Program Drive Buy Rating
- Promising Developments and Strategic Financial Management Drive Buy Rating for Arcturus Therapeutics
- Arcturus Therapeutics price target lowered to $66 from $68 at Canaccord
- Citi opens ’90-day Upside Catalyst Watch’ on Arcturus Therapeutics
- Strategic Shift to mRNA Therapeutics Positions Arcturus for Significant Upside